Some experts are questioning whether a newly approved Alzheimer's drug was shown in clinical trials to be less effective on women — even though the FDA didn't flag any such concerns when it was authorized last week. Why it matters: Nearly two-thirds of Americans living with Alzheimer's disease are female, according to the Alzheimer's Association. The $26,500 drug, Leqembi,…